Meth bill vote pledged
This article was originally published in The Tan Sheet
Executive Summary
Senate leadership has agreed to vote in January or early February on legislation that would put OTC cough/cold products containing pseudoephedrine behind the counter, according to Combat Meth Act cosponsor Sen. Dianne Feinstein (D-Calif.). A version of the bill was attached to the Patriot Act reauthorization conference report but was left behind when the Senate reached a compromise Dec. 22 to extend Patriot by five weeks without the report. Feinstein is considering seeking another vehicle or attempting to pass the meth Act as a stand-alone bill; however, according to her office, the bill likely will resurface as an amendment to the Patriot Act, which will require reauthorization prior to Feb. 3...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.